IDEAYA Biosciences

IDEAYA makes targeted drugs that help doctors treat specific types of cancer based on a patient's genes. These medicines find and attack cancer cells without harming healthy parts of the body. This approach aims to help patients with rare or hard-to-treat tumors.

Targeting the Drivers of Cancer

• Darovasertib: Oral drug for a rare eye cancer called uveal melanoma; currently in late-stage clinical trials.
• Antibody-Drug Conjugates: Targeted therapies that deliver potent drugs directly to cancer cells while sparing healthy tissue.
• MAT2A Inhibitors: Medicine designed for patients whose tumors have a specific genetic gap known as an MTAP deletion.
• Precision Medicine Platform: Scientific tools used to identify and validate new markers that reveal how cancer grows.

Strategic Deals and Partnerships

• Formed a global license agreement with Servier in August 2025 to develop and sell darovasertib outside the United States.
• Partnered with Hengrui Pharma in December 2024 to gain rights for a new lung cancer drug outside of China.
• Acquired an option for a new bispecific cancer program from Biocytogen in July 2024.
• Entered a clinical collaboration with AstraZeneca in April 2026 to test combined therapies for lung cancer.
• Planned the return of two clinical programs from GSK following a partnership termination in March 2026.

What Makes IDEAYA Different

The company focuses on synthetic lethality, a method where two genetic weaknesses are combined to kill cancer cells. This strategy creates highly selective treatments that may be more effective and less toxic than traditional chemotherapy.

The Financial Picture

• Collaboration revenue rose to $6.6 million in Q1 2026 from zero in the same period of 2025.
• Net loss deepened to $98.5 million in Q1 2026, a 38% worsening from the previous year.
• Operating cash flow deficit deepened to $75.2 million in Q1 2026, compared to $60.3 million in Q1 2025.
• Total cash and marketable securities reached $972.9 million by March 31, 2026, to fund ongoing clinical trials.

Bottom Line

IDEAYA is transitioning from early research to late-stage clinical testing with multiple drug candidates. Its shift toward antibody-drug conjugates and global partnerships marks a new phase of development in precision oncology.